FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060193600> ?p ?o ?g. }

• W2060193600 endingPage "1459" @default.
• W2060193600 startingPage "1457" @default.
• W2060193600 abstract "It has been two years since clinical development of cancer immunotherapy has started to turn from decades of failures to its first successes in randomized Phase 3 trials with Sipuleucel-T, a dendritic cell-based vaccine, and ipilimumab, a monoclonal antibody targeting CTLA-4. Both are increasing patient survival in their target diseases.1,2 The path to these successes was, in part, paved by the methodological improvements regarding clinical endpoints for immunotherapy development that enabled the understanding of the clinical observations made for these agents and the differentiation of immunotherapy kinetics from chemotherapy kinetics.3 Such methodological improvements do not come easy and require broad consensus across the community that uses these methods for them to be widely applicable. The adaptation of immunotherapy clinical endpoints took about five years, and has shown that consensus work facilitated by community organizations like the Cancer Immunotherapy Consortium (CIC) or the Association for Cancer Immunotherapy (CIMT) can be impactful and systematically fill gaps that prevent advances in our field.4Similarly, other methodological improvements are needed in this space and have been worked on by several community organizations for years. The first that comes to mind is the effort of harmonizing the use of immune monitoring assays in multi-center clinical trials through a data-driven, SOP-based process that enables individual centers to use their own assay protocols and still achieve a low level of data variability across centers.5 This program has been running since 2005 and has delivered practical recommendations for the community based on the recognition of critical experimental variables that impact assay performance and should be reported to assess the results. By design, this assay harmonization project, which focused on frequently-used assays such as ELISPOT, intracellular cytokine staining or HLA-peptide multimer staining, has focused on assay conduct and did not address data reporting.5,6 However, it has not escaped the attention of many immunotherapy experts that the methods and results published for immune monitoring experiments are still inconsistently reported, often leading to missing information and difficulties in data interpretation across publications.7 Ultimately, the full utility of measuring immune response to immunotherapeutic interventions as a biomarker or surrogate for clinical outcomes will strongly depend on the interpretability and reproducibility of such data across trials. As before, the solution to this methodological problem seems to lie in a community-wide consensus process that would establish minimum reporting criteria for immune monitoring data.6,7Indeed, after about three years of an intense vetting process across the immunotherapy communities in cancer, infectious diseases and autoimmunity, the Minimal Information about T cell assays (MIATA) guidelines were published recently in Immunity.8 MIATA’s aim was to improve interpretation and data comparison across immune monitoring experiments reported in different publications by creating a minimum reporting framework for consistent and community-wide use. The components included in the MIATA guidelines were oriented on the variables identified to bear most impact on performance of a given T-cell assay experiment in clinical trials. Information to be reported falls in the following categories:SampleAssayData AcquisitionResultsLaboratory EnvironmentThe concept of Minimal Information (MI) projects is not new and has been successfully applied in other areas of biomedical sciences such as the reporting of high-throughput genomic experiments (Minimum Information About Microarray Experiments, MIAME) and a variety of other assays (www.mibbi.org),9,10 which has greatly improved reporting of such experiments.A hallmark of MIATA was its intense vetting process, including two public consultation periods and two open workshops over a three-year period with frequent reach-out to the community11 and a project website (www.miataproject.org) to transparently show progress of the initiative and feedback received from participants. Overall, MIATA includes active contributions from more than 120 peers from academic and industry scientists.8 The guidelines are published as open access in the July issue of Immunity (www.cell.com/immunity/retrieve/pii/S1074761312002919) and are accessible through the MIATA website. MIATA aims to be come part of instructions for authors of immunology-based science journals.Great efforts were made to ensure MIATA would ask only for “minimum information” needed to achieve its goal, which simplifies practical implementation and limits the burden on the reporting scientists. To assist investigators to achieve a rather straightforward use of MIATA, various supporting documents are provided on the MIATA website, which include (1) a checklist for MIATA compliance, (2) example reports, (3) guidance for donor information and (4) terms related to the laboratory environment. Nevertheless, the use of MIATA will take some effort from authors to adapt the Materials and Method section of new manuscripts to MIATA style. MIATA adherence can easily be checked via the online checklist (http://www.miataproject.org/checklist.pdf)." @default.
• W2060193600 created "2016-06-24" @default.
• W2060193600 creator A5036257821 @default.
• W2060193600 creator A5045288107 @default.
• W2060193600 creator A5086481435 @default.
• W2060193600 date "2012-12-01" @default.
• W2060193600 modified "2023-09-26" @default.
• W2060193600 title "Advancing the field of cancer immunotherapy" @default.
• W2060193600 cites W1544923801 @default.
• W2060193600 cites W1988607812 @default.
• W2060193600 cites W2002662941 @default.
• W2060193600 cites W2023244389 @default.
• W2060193600 cites W2050554833 @default.
• W2060193600 cites W2050579301 @default.
• W2060193600 cites W2093188850 @default.
• W2060193600 cites W2097995306 @default.
• W2060193600 cites W2102143045 @default.
• W2060193600 cites W2103959341 @default.
• W2060193600 cites W2135738145 @default.
• W2060193600 doi "https://doi.org/10.4161/onci.22308" @default.
• W2060193600 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3525600" @default.
• W2060193600 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23264891" @default.
• W2060193600 hasPublicationYear "2012" @default.
• W2060193600 type Work @default.
• W2060193600 sameAs 2060193600 @default.
• W2060193600 citedByCount "10" @default.
• W2060193600 countsByYear W20601936002013 @default.
• W2060193600 countsByYear W20601936002014 @default.
• W2060193600 countsByYear W20601936002015 @default.
• W2060193600 countsByYear W20601936002016 @default.
• W2060193600 countsByYear W20601936002017 @default.
• W2060193600 countsByYear W20601936002018 @default.
• W2060193600 countsByYear W20601936002020 @default.
• W2060193600 crossrefType "journal-article" @default.
• W2060193600 hasAuthorship W2060193600A5036257821 @default.
• W2060193600 hasAuthorship W2060193600A5045288107 @default.
• W2060193600 hasAuthorship W2060193600A5086481435 @default.
• W2060193600 hasBestOaLocation W20601936001 @default.
• W2060193600 hasConcept C121608353 @default.
• W2060193600 hasConcept C126322002 @default.
• W2060193600 hasConcept C2777701055 @default.
• W2060193600 hasConcept C2780674031 @default.
• W2060193600 hasConcept C71924100 @default.
• W2060193600 hasConceptScore W2060193600C121608353 @default.
• W2060193600 hasConceptScore W2060193600C126322002 @default.
• W2060193600 hasConceptScore W2060193600C2777701055 @default.
• W2060193600 hasConceptScore W2060193600C2780674031 @default.
• W2060193600 hasConceptScore W2060193600C71924100 @default.
• W2060193600 hasIssue "9" @default.
• W2060193600 hasLocation W20601936001 @default.
• W2060193600 hasLocation W20601936002 @default.
• W2060193600 hasLocation W20601936003 @default.
• W2060193600 hasLocation W20601936004 @default.
• W2060193600 hasOpenAccess W2060193600 @default.
• W2060193600 hasPrimaryLocation W20601936001 @default.
• W2060193600 hasRelatedWork W2030612376 @default.
• W2060193600 hasRelatedWork W2755360248 @default.
• W2060193600 hasRelatedWork W2893846263 @default.
• W2060193600 hasRelatedWork W2973160925 @default.
• W2060193600 hasRelatedWork W2996772275 @default.
• W2060193600 hasRelatedWork W3033719114 @default.
• W2060193600 hasRelatedWork W3127346141 @default.
• W2060193600 hasRelatedWork W3195008613 @default.
• W2060193600 hasRelatedWork W4214943367 @default.
• W2060193600 hasRelatedWork W4310278132 @default.
• W2060193600 hasVolume "1" @default.
• W2060193600 isParatext "false" @default.
• W2060193600 isRetracted "false" @default.
• W2060193600 magId "2060193600" @default.
• W2060193600 workType "article" @default.